Maratha Headlines

Diffuse Large B-cell Lymphoma (DLBCL) Market to Observe Stupendous Growth During the Forecast Period (2019-32) | Key Companies – Merck, Amgen, Bayer, Novartis, Karyopharm, BMS, Takeda, Incyte

 Breaking News
  • No posts were found

Diffuse Large B-cell Lymphoma (DLBCL) Market to Observe Stupendous Growth During the Forecast Period (2019-32) | Key Companies – Merck, Amgen, Bayer, Novartis, Karyopharm, BMS, Takeda, Incyte

July 28
01:33 2022
Diffuse Large B-cell Lymphoma (DLBCL) Market to Observe Stupendous Growth During the Forecast Period (2019-32) | Key Companies - Merck, Amgen, Bayer, Novartis, Karyopharm, BMS, Takeda, Incyte
Delveinsight Business Research LLP
The Diffuse Large B-cell Lymphoma (DLBCL) Market dynamics are anticipated to transform in the coming years owing to the increased incidence of lymphomas in older patients. Along with this, the increase in the research and development programs related to DLBCL therapeutics will also strengthen the market growth.

DelveInsight’s “Diffuse Large B-cell Lymphoma (DLBCL) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Diffuse Large B-cell Lymphoma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Diffuse Large B-cell Lymphoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Diffuse Large B-cell Lymphoma Market

Diffuse Large B-cell Lymphoma (DLBCL): An Overview

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that affects B-lymphocytes. It develops when B-lymphocytes become abnormal. It is a mature B-cell neoplasm arising from the germinal center & post germinal center B-cells.

The etiology of DLBCL is complex and multifactorial. DLBCL can arise de-novo or from the transformation of indolent diseases like chronic lymphocytic lymphoma/small lymphocytic lymphoma (so-called Richter’s transformation), follicular lymphoma, and marginal zone lymphoma.

Some of the targeted therapies and cell therapies have already been approved for the treatment of DLBCL, while many are in the clinical stage of development which have demonstrated excellent initial outcomes and are in the process of further clinical evaluation.

Diffuse Large B-cell Lymphoma (DLBCL) Market Key Facts

  • The total incident cases of DLBCL in the 7MM were assessed to be 71,000+ in 2020 and are expected to increase during the study period.

  • Among the EU5 countries, Germany had the highest incident population of DLBCL with 7,670+ cases, followed by the United Kingdom and France, while Spain had the lowest incident cases.

  • Japan had 9,780+ cases for DLBCL in 2020, which accounted for ~14% of the total 7MM patient population of DLBCL.

  • DLBCL cases most commonly affect middle-aged and older adults. In comparison, they are relatively less common in children and young adults. It was observed that the age group with the highest incidence among the 7MM was 65–74 years in 2020. Patients of age group 55–64 years were observed to be the second-highest in 2020. 

Diffuse Large B-cell Lymphoma (DLBCL) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Diffuse Large B-cell Lymphoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report details the Diffuse Large B-cell Lymphoma market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Diffuse Large B-cell Lymphoma (DLBCL) Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Diffuse Large B-cell Lymphoma (DLBCL) Epidemiology Segmentation –

  • Total Incident Cases 

  • Gender-specific Cases

  • Age-specific Cases 

  • Type-specific Cases

  • Stage-specific Cases

Diffuse Large B-cell Lymphoma (DLBCL) Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diffuse Large B-cell Lymphoma market or expected to be launched during the study period. The analysis covers Diffuse Large B-cell Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Diffuse Large B-cell Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market

Diffuse Large B-cell Lymphoma (DLBCL) Therapeutics Analysis

Currently, several companies are involved in developing various therapies for the frontline, second line (transplant-eligible and transplant-ineligible), and subsequent R/R patients with DLBCL. The launch of the therapies is expected to stimulate market growth.

Some of the key companies in the Diffuse Large B-cell Lymphoma (DLBCL) Market include:

  • Merck

  • Amgen

  • Bayer

  • Novartis

  • Karyopharm therapeutics

  • Bristol-Myers Squibb

  • Seattle Genetics/Takeda

  • ADC Therapeutics

  • Morphosys/Incyte

  • SymBio Pharmaceuticals

  • Denovo Biopharma

  • TG therapeutics

  • Gilead Life Sciences

  • Janssen/Pharmacyclics

  • Biogen Idec/Genentech

  • Chugai Pharmaceuticals

And many others.

Diffuse Large B-cell Lymphoma (DLBCL) Therapies covered in the report include:

  • Lisocabtagene maraleucel

  • Brentuximab Vedotin

  • Loncastuximab Tesirine

  • Ublituximab + Umbralisib

  • Aliqopa

  • DPX-Survivac

  • AUTO3

  • CLR 131

  • P + RCHOP

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Diffuse Large B-cell Lymphoma Competitive Intelligence Analysis

4. Diffuse Large B-cell Lymphoma Market Overview at a Glance

5. Diffuse Large B-cell Lymphoma Disease Background and Overview

6. Diffuse Large B-cell Lymphoma Patient Journey

7. Diffuse Large B-cell Lymphoma Epidemiology and Patient Population

8. Diffuse Large B-cell Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Diffuse Large B-cell Lymphoma Unmet Needs

10. Key Endpoints of Diffuse Large B-cell Lymphoma Treatment

11. Diffuse Large B-cell Lymphoma Marketed Products

12. Diffuse Large B-cell Lymphoma Emerging Therapies

13. Diffuse Large B-cell Lymphoma Seven Major Market Analysis

14. Attribute Analysis

15. Diffuse Large B-cell Lymphoma Market Outlook (7 major markets)

16. Diffuse Large B-cell Lymphoma Access and Reimbursement Overview

17. KOL Views on the Diffuse Large B-cell Lymphoma Market.

18. Diffuse Large B-cell Lymphoma Market Drivers

19. Diffuse Large B-cell Lymphoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Healthcare Reports by DelveInsight

Retinoblastoma Market
Retinoblastoma Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Retinoblastoma Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the Retinoblastoma Market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/malignant-mesothelioma-market

Recent Posts

Fans accompany Chinese Artist YanHaoxiang meeting him is the luckiest thing in their life

Read Full Article

Categories